|[April 17, 2014]
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2014 Financial Results
WALTHAM, Mass. --(Business Wire)--
Inc. (Nasdaq: IMGN), a biotechnology company that develops novel
anticancer therapeutics using its antibody-drug conjugate (ADC (News - Alert))
technology, today announced that the Company will host a conference call
at 8:00 a.m. ET on Friday, April 25, 2014, to discuss ImmunoGen's
financial results for the three-month period ended March 31, 2014.
Management also will provide an update on the Company.
To access the live call by phone, dial 913-312-0376; the passcode is
4427468. The call also may be accessed thrugh the Investor Information
section of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available at
the same location through May 9, 2014.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen
cell-killing agent specifically to cancer cells; the Company has also
developed antibodies with anticancer activity of their own. The first
product approved with ImmunoGen's ADC technology is Roche's Kadcyla®.
ImmunoGen has three wholly owned product candidates in clinical testing
with additional compounds in the clinic through the Company's
partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More
information about ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, Inc., a
member of the Roche Group.
[ Back To TMCnet.com's Homepage ]